Distribution of apixaban plasma concentrations across prescribed dose groups for ischemic stroke prevention in atrial fibrillation

12 April 2026 (08:00 - 15:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Associate Professor Kyung Hee Lim

Dong-a University Hospital, Busan (Korea (Republic of))

4 More presentations in this session

Presentation thumbnail

Impact of kidney function on cardiovascular outcome in patients with device-detected atrial fibrillation in NOAH-AFNET 6

Professor A. Goette (Paderborn, DE)

Abstract Slides Video

Presentation thumbnail

Ablation outcome and post-interventional management of anticoagulation in patients with obesity or severe obesity and atrial fibrillation

Ms R. Bares (Munich, DE)

Abstract Slides Video

Presentation thumbnail

Outcomes after cavotricuspid isthmus ablation: predictors of new-onset atrial fibrillation and stroke according to anticoagulation strategy

Doctor J. Villoria Martin (Huelva, ES)

Abstract Slides Video

Presentation thumbnail

CHA2DS2-VASc score-based anticoagulation management after catheter ablation for atrial fibrillation: a post-hoc analysis of the ALONE-AF trial

Doctor Y. Lee (Seoul, KR)

Abstract Slides Video

Access the full session

Session thumbnail

Oral anticoagulation in atrial fibrillation

The Event

Event poster

EHRA 2026

12 April - 14 April 2026

You may be interested in

Congress Presentation

Impact of real-world off-label dose of apixaban on long-term clinical outcomes in heart failure patients with atrial fibrillation and end stage kidney disease

Congress Session

Atrial fibrillation management and outcomes in high-risk atrial fibrillation populations

Congress Session

Personalised anticoagulation therapy in eligible patients with atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources